This is a friendly reminder to assigned Vaccine Coordinators that have not yet completed the required annual VFC educational module to do so before 10/1/24, to avoid potential interruptions to vaccine ordering.
Education completed before 7/1/24 will not be counted towards this new fiscal year (July 1, 2024 – June 30, 2025). All education must be completed on or after July 1, 2024.
We are noticing recurring issues with deliveries from McKesson, and its important to follow the proper procedures when receiving vaccine shipments. When reporting delivery concerns to McKesson, please ensure you provide the following:
- The order number
- A picture of the tag alert monitor from the box.
- A picture of the packing ship from the box.
- Date of delivery and any temperature monitoring concerns.
As a reminder, providers must open vaccine packages immediately, check the temperature monitor, inspect the vaccine, compare the packing list, and store it at the appropriate temperature. If there are any concerns with the temperature monitor (out of range, not activates, or issues with the chemical indicator), contact McKesson Specialty Customer Care (MSCC) immediately.
Ensure that no packing materials are discarded until viability is confirmed by MSCC, and always obtain a picture of the temperature monitor to provide to MSCC.
McKesson Specialty Customer Care: (855) 477-9800 |
Due to the lower-than-expected attendance for the upcoming MIP Regional Trainings, we have made the decision to cancel the in-person sessions and replace them with a single virtual training session. Our goal is to make participation easier and more convenient to all providers.
We sincerely apologize for any inconvenience this may cause and appreciate your understanding as we adjust our plans. We believe that offering a virtual session will better accommodate your schedules and ensure broader participation. We will announce the new date for this virtual training later this fall and look forward to your participation.
Thank you for your continued dedication and flexibility.
CDC released a report in the MMWR this week regarding the 2024-2025 COVID-19 vaccination recommendations. This document summarizes the recommendations for everyone 6 month and up to be up-to-date with 2024-2025 COVID-19 vaccine. It highlights the safety and effectiveness of the vaccine as well as discussed economic impacts of vaccinations based on demographics, etc. Finally, the article provides a review of the recommendations published in the Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. You can find the full article here.
The Maine Immunization Program is sharing important information on the upcoming RSV season. Starting October 1, 2024, nirsevimab (Beyfortus) will be available to protect infants and young children, with prioritization for babies under 5 kg. High-risk children and older adults are also encouraged to receive appropriate RSV immunizations. For more details on vaccine recommendations, ordering guidelines, and administration timelines, please click here.
The FDA amended the emergency use authorization (EUA) of Novavax COVID-19 Vaccine, Adjuvanted to include the 2024-2025 formula. The Novavax COVID-19 Vaccine, Adjuvanted, (2024-2025 Formula) includes a monovalent (single) component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2. For more information, please visit:
FDA authorized use of the 2024–25 formulation of the protein-based Novavax COVID-19 vaccine |
